María del Carmen Ovejero Benito-rekin lankidetzan egindako argitalpenak (9)

2018

  1. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 122, Núm. 5, pp. 501-511

  2. Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis

    British Journal of Dermatology

  3. Histone modifications associated with biological drug response in moderate-to-severe psoriasis

    Experimental Dermatology, Vol. 27, Núm. 12, pp. 1361-1371

  4. How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?

    Pharmacogenomics, Vol. 19, Núm. 16, pp. 1285-1297

  5. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis

    American Journal of Clinical Dermatology, Vol. 19, Núm. 2, pp. 209-222

  6. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis

    Pharmacogenomics, Vol. 19, Núm. 1, pp. 7-16

2017

  1. Pharmacogenetics of trazodone in healthy volunteers: Association with pharmacokinetics, pharmacodynamics and safety

    Pharmacogenomics, Vol. 18, Núm. 16, pp. 1491-1502

  2. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis

    Pharmacogenomics, Vol. 18, Núm. 7, pp. 631-638

2016

  1. Utilización de nuevos agentes biológicos para el tratamiento de la psoriasis en placas moderada-grave

    Actualidad en farmacología y terapéutica, Vol. 14, Núm. 3, pp. 181-186